Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06854341 · ClinicalTrials.gov registry record
A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 5,448
- Enrollment target
NCT06854341: Completed study, sponsored by Novartis Pharmaceuticals.
NCT06854341 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 5,448 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06854341 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 5,448 participants
- Enrollment target
Study Summary
This was an observational, non-interventional, real world study involving secondary use of de-identified aggregate data from patients prescribed ofatumumab, collected by the Kesimpta Go Program in Canada. This study utilized a cohort design. The study period included all available data captured by the Kesimpta Go Program from program inception (April 2, 2021) to the time of data transfer (May 1, 2024). Patients were indexed into the study on the date they started their medication, from April 2, 2021 to May 1, 2024. The baseline period represented the period prior to ofatumumab treatment initiation. Baseline variables were collected from the enrollment form, which include demographic and clinical history, such as whether the patient had prior treatment with disease-modifying therapy (DMT). Patients were followed until the first of the following censoring events: ofatumumab discontinuation; end of the study period; or leaving the Kesimpta Go Program.
Primary Outcome
Patient characteristics included age group, gender, type of insurance, and experience (naive or experienced) of disease-modifying therapy (DMT) before starting ofatumumab.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,448 participants |
| Start Date | 2024-02-09 |
| Est. Completion | 2024-08-27 |
What the finished NCT06854341 record still lists
NCT06854341 is an observational study that tracks outcomes without assigning an intervention. Its 5,448 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT06854341 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06854341 about?
NCT06854341 is a clinical study titled "A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data". This was an observational, non-interventional, real world study involving secondary use of de-identified aggregate data from patients prescribed ofatumumab, collected by the Kesimpta Go Program in Canada. This study utilized a cohort design. The study period included all available data captured by t...
What is the current status of trial NCT06854341?
This trial is currently completed. The enrollment target is 5,448 participants. The study started on 2024-02-09. Estimated completion is 2024-08-27.
Who is sponsoring clinical trial NCT06854341?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT05952557 · 5,500 participants · Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- NCT06084234 · 5,500 participants · Phase 4
National Liver Cancer Screening Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI